Patient characteristics
| Variable . | DD (106 patients) . | DVD (62 patients) . | P . |
|---|---|---|---|
| At first diagnosis | |||
| λ subtype | 90 (85%) | 47 (76%) | .15 |
| Ig heavy chain present | 44 (42%) | 33 (53%) | .37 |
| Male sex | 73 (69%) | 33 (53%) | .05 |
| dFLC, mg/L | 236 (22-9600)* | 247 (0-2237)* | .74 |
| Symptomatic MM | 10 (9%) | 5 (8%) | 1.00 |
| Smoldering MM | 76 (72%) | 53 (86%) | .06 |
| Monoclonal gammopathy | 20 (19%) | 4 (7%) | .04 |
| BMPC percentage | 13 (2-84) | 19.5 (8-81) | .0014 |
| Translocation t(11;14) | 53/85 (62%) | 23/43 (54%) | .35 |
| Gain of 1q21 | 25/83 (30%) | 10/40 (25%) | .67 |
| Hyperdiploidy | 12/82 (15%) | 6/40 (15%) | 1.00 |
| MM high-risk aberrations | 8/85 (9%) | 4/41 (10%) | 1.00 |
| Deletion 13q14 | 28/84 (33%) | 12/41 (29%) | .69 |
| Before daratumumab | |||
| Age, y | 65 (36-81) | 60 (38-79) | .03 |
| Time from first therapy, mo | 29 (0-143) | 5 (0-104) | <.0001 |
| Time from last therapy, mo | 2 (0-54) | 1 (0-72) | .0009 |
| No. of previous therapies | 2 (1-7) | 1 (1-7) | .0005 |
| Refractory to last therapy | 59 (56%) | 34 (55%) | 1.00 |
| PI exposed | 97 (92%) | 59 (95%) | .54 |
| PI refractory | 52 (54%) | 33 (56%) | .63 |
| IMID exposed | 77 (73%) | 3 (5%) | <.0001 |
| IMID refractory | 42 (40%) | 1 (2%) | <.0001 |
| Melphalan exposed | 69 (65%) | 13 (21%) | <.0001 |
| Previous autologous transplant | 24 (23%) | 5 (8%) | .019 |
| Number of organs involved | 2 (1-5) | 3 (1-5) | .16 |
| >2 organs involved | 38 (36%) | 32 (52%) | .05 |
| Cardiac involvement | 88 (83%) | 54 (87%) | .52 |
| Renal involvement | 67 (63%) | 40 (65%) | 1.00 |
| Hepatic involvement | 15 (14%) | 15 (24%) | .14 |
| Soft-tissue involvement | 42 (40%) | 28 (45%) | .52 |
| Gastrointestinal involvement | 21 (20%) | 12 (19%) | 1.00 |
| Neuropathic involvement | 16 (15%) | 3 (5%) | .05 |
| dFLC in mg/L | 136 (0-3108)† | 117 (0-1997)† | .47 |
| dFLC >180 mg/L | 38 (36%) | 23 (37%) | .87 |
| NT-ProBNP in ng/L | 4155 (105-294 788)‡ | 5475 (78-127 410)‡ | .90 |
| NT-ProBNP >8500 ng/L | 36 (34%) | 25 (40%) | .41 |
| ACR, mg/mmol | 71 (0-13 415)§ | 194 (0-1434)§ | .44 |
| ACR >220mg/mmol | 48 (45%) | 32 (52%) | .52 |
| eGFR, mL/min/1.73 m2 (all patients not on dialysis) | 51.5 (12-126)|| | 53.5 (11-106)|| | .62 |
| eGFR <50 mL/min/1.73 m2 | 57 (54%)¶ | 33 (53%)¶ | 1.00 |
| Patients on dialysis | 15 (14%) | 6 (10%) | .47 |
| Daily proteinuria, mg/d | 1606 (0-20 160)# | 2701(57-18 852)# | .45 |
| Variable . | DD (106 patients) . | DVD (62 patients) . | P . |
|---|---|---|---|
| At first diagnosis | |||
| λ subtype | 90 (85%) | 47 (76%) | .15 |
| Ig heavy chain present | 44 (42%) | 33 (53%) | .37 |
| Male sex | 73 (69%) | 33 (53%) | .05 |
| dFLC, mg/L | 236 (22-9600)* | 247 (0-2237)* | .74 |
| Symptomatic MM | 10 (9%) | 5 (8%) | 1.00 |
| Smoldering MM | 76 (72%) | 53 (86%) | .06 |
| Monoclonal gammopathy | 20 (19%) | 4 (7%) | .04 |
| BMPC percentage | 13 (2-84) | 19.5 (8-81) | .0014 |
| Translocation t(11;14) | 53/85 (62%) | 23/43 (54%) | .35 |
| Gain of 1q21 | 25/83 (30%) | 10/40 (25%) | .67 |
| Hyperdiploidy | 12/82 (15%) | 6/40 (15%) | 1.00 |
| MM high-risk aberrations | 8/85 (9%) | 4/41 (10%) | 1.00 |
| Deletion 13q14 | 28/84 (33%) | 12/41 (29%) | .69 |
| Before daratumumab | |||
| Age, y | 65 (36-81) | 60 (38-79) | .03 |
| Time from first therapy, mo | 29 (0-143) | 5 (0-104) | <.0001 |
| Time from last therapy, mo | 2 (0-54) | 1 (0-72) | .0009 |
| No. of previous therapies | 2 (1-7) | 1 (1-7) | .0005 |
| Refractory to last therapy | 59 (56%) | 34 (55%) | 1.00 |
| PI exposed | 97 (92%) | 59 (95%) | .54 |
| PI refractory | 52 (54%) | 33 (56%) | .63 |
| IMID exposed | 77 (73%) | 3 (5%) | <.0001 |
| IMID refractory | 42 (40%) | 1 (2%) | <.0001 |
| Melphalan exposed | 69 (65%) | 13 (21%) | <.0001 |
| Previous autologous transplant | 24 (23%) | 5 (8%) | .019 |
| Number of organs involved | 2 (1-5) | 3 (1-5) | .16 |
| >2 organs involved | 38 (36%) | 32 (52%) | .05 |
| Cardiac involvement | 88 (83%) | 54 (87%) | .52 |
| Renal involvement | 67 (63%) | 40 (65%) | 1.00 |
| Hepatic involvement | 15 (14%) | 15 (24%) | .14 |
| Soft-tissue involvement | 42 (40%) | 28 (45%) | .52 |
| Gastrointestinal involvement | 21 (20%) | 12 (19%) | 1.00 |
| Neuropathic involvement | 16 (15%) | 3 (5%) | .05 |
| dFLC in mg/L | 136 (0-3108)† | 117 (0-1997)† | .47 |
| dFLC >180 mg/L | 38 (36%) | 23 (37%) | .87 |
| NT-ProBNP in ng/L | 4155 (105-294 788)‡ | 5475 (78-127 410)‡ | .90 |
| NT-ProBNP >8500 ng/L | 36 (34%) | 25 (40%) | .41 |
| ACR, mg/mmol | 71 (0-13 415)§ | 194 (0-1434)§ | .44 |
| ACR >220mg/mmol | 48 (45%) | 32 (52%) | .52 |
| eGFR, mL/min/1.73 m2 (all patients not on dialysis) | 51.5 (12-126)|| | 53.5 (11-106)|| | .62 |
| eGFR <50 mL/min/1.73 m2 | 57 (54%)¶ | 33 (53%)¶ | 1.00 |
| Patients on dialysis | 15 (14%) | 6 (10%) | .47 |
| Daily proteinuria, mg/d | 1606 (0-20 160)# | 2701(57-18 852)# | .45 |
Numbers with percentages in parentheses. Percentages were calculated for all 106 patients receiving DD and all 62 patients receiving DVD unless otherwise stated in numbers section. Medians with ranges in brackets for all patients unless otherwise stated. P values to test for differences between DD and DVD were calculated with the Kruskal-Wallis test for continuous variables, and the Fisher exact test for categorical variables. Statistically significant results (P < .05) are bold.
6 DD and 2 DVD not available.
4 DD and 4 DVD patients with only involved serum free-light chain available or not evaluated with binding site test.
18 DD and 7 DVD not available.
9 DD and 3 DVD not available.
For patients not on dialysis.
Patients on dialysis classified as <50 mL/min/1.73 m2.
17 DD and 10 DVD not available.